Barclays’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Barclays’s Portfolio LJPC Stock Details LJPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-300	Closed	-$2K	–	7614
2019 Q1	$2K	Sell	300 -500	-63%	-$3.26K	﹤0.01%	6890
2018 Q4	$8K	Sell	800 -1,600	-67%	-$24.1K	﹤0.01%	6305
2018 Q3	$48K	Sell	2,400 -27,600	-92%	-$721K	﹤0.01%	6113
2018 Q2	$875K	Sell	30,000 -5,700	-16%	-$176K	﹤0.01%	3431
2018 Q1	$1.06M	Buy	+35,700	New	+$1.15M	﹤0.01%	3141
2017 Q3	–	Sell	-1,100	Closed	-$33K	–	7370
2017 Q2	$33K	Buy	+1,100	New	+$31.5K	﹤0.01%	5571

Barclays's LJPC Position: Q3 2022 in Review

Barclays sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 5,352 shares — an estimated $17K sold.

Barclays first reported a position in LJPC in Q2 2014 and held it in 30 quarters. The position peaked at $2.85M in Q3 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.

Barclays reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
Barclays sold 5,352 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $17K.
Barclays first reported a position in La Jolla Pharmaceutical Company in Q2 2014 and held it in 30 quarters.
Barclays's La Jolla Pharmaceutical Company position peaked at $2.85M in Q3 2018.
0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.